Unavailable
Unavailable
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE:GRF) today declared a year-end distribution of $0.68 per share in cash. The record date for this distribution is November 29, 2024, and the payment date is December 19, 2024. On a preliminary basis, this distribution represents a combination of net investment income of $0.0754 per share, and long-term capital gains of $0.6046 per share. This preliminary information is subject to change. Shareholders will receive definitive information with respect to U. S. Federal income tax treatment. In addition, shareholders can access definitive tax information by going to the Fund's website after year-end. The Fund is a closed-end investment compan
The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE:GRF) today declared a year-end distribution of $0.35 per share in cash. The record date for this distribution is November 24, 2023, and the payment date is December 15, 2023. On a preliminary basis, this distribution represents a combination of net investment income of $0.07 per share, short-term capital gains of $0.03 per share, and long-term capital gains of $0.25 per share. This preliminary information is subject to change. Shareholders will receive definitive information with respect to U. S. Federal income tax treatment. In addition, shareholders can access definitive tax information by going to the Fund's website after year-end. T
BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa
4 - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Issuer)
4 - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Issuer)
4 - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Issuer)
DEF 14A - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Filer)
N-CSR - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Filer)
N-CEN - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Filer)
4 - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Issuer)
4 - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Issuer)
4 - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Issuer)
BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa
SC 13D - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Subject)
SC 13D/A - EAGLE CAPITAL GROWTH FUND, INC. (0000850027) (Subject)